Results 41 to 50 of about 32,890 (266)

Early ultrasound response and progressive transmural remission after treatment with ustekinumab in Crohn's disease.

Clinical Gastroenterology and Hepatology, 2022
BACKGROUND & AIMS In this STARDUST substudy, the effect of ustekinumab on transmural bowel inflammation was assessed in adults with moderate-to-severe Crohn's disease (CD) utilizing intestinal ultrasound (IUS) a non-invasive, imaging procedure ...
T. Kucharzik, R. Wilkens, M. D’Agostino, G. Maconi, M. le Bars, M. Lahaye, I. Bravatá, M. Nazar, L. Ni, E. Ercole, M. Allocca, N. Machková, Floris A. E. de Voogd, Palmela Carolina, R. Vaughan, C. Maaser   +15 more
semanticscholar   +1 more source

Two-year real-world outcome data from a single tertiary centre shows reduced ustekinumab persistence in a non-bio-naïve Crohn’s disease cohort with penetrating disease, -ostomies and sarcopenia

Therapeutic Advances in Chronic Disease, 2023
Background: Ustekinumab was approved in 2016 for the treatment of moderate–severe Crohn’s disease (CD). Clinical trials and real-world studies have suggested ustekinumab to be a safe and effective treatment; however, studies to date infrequently use ...
Saskia Inniss, Konstantinos C. Fragkos, Lisa Whitley, Rachel Wimpory, Eleanor Rebello, Ana Lisboa, Tanvi Khetan, Jasmine Hassan, Kate Simpson, Anisha Bhagwanani, Roser Vega, Ioanna Parisi, Paul Harrow, Edward Seward, Sara McCartney, Stuart Bloom, Andrew M. Smith, Andrew Plumb, Farooq Z. Rahman   +18 more
doaj   +1 more source

Alopecia areata: a multifactorial autoimmune condition [PDF]

, 2019
Alopecia areata is an autoimmune disease that results in non-scarring hair loss, and it is clinically characterised by small patches of baldness on the scalp and/or around the body. It can later progress to total loss of scalp hair (Alopecia totalis) and/
Butcher, John P., Henriquez, Fiona L., Reid, Stuart, Simakou, Teontor   +3 more
core   +1 more source

Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn’s Disease

Drugs, 2023
Surgery for Crohn’s disease (CD) is not curative, as postoperative recurrence (POR) after ileocolonic resection is the rule in the absence of prophylactic treatment.
J. Gisbert, M. Chaparro
semanticscholar   +1 more source

The Efficacy of Combination Therapy with Ustekinumab and Budesonide for Crohn’s Disease: A Randomized Controlled Trial

Inflammatory Intestinal Diseases, 2023
Introduction: Limited data exist on the efficacy of combination therapy with ustekinumab and budesonide in patients with Crohn’s disease. Our objective was to compare the clinical outcomes of ustekinumab and budesonide combination therapy with those of ...
Rintaro Moroi, Kasumi Hishinuma, Yumi Sugawara, Kotaro Nochioka, Yusuke Shimoyama, Takeo Naito, Hisashi Shiga, Yoichi Kakuta, Yoshitaka Kinouchi, Ichiro Tsuji, Atsushi Masamune   +10 more
doaj   +1 more source

Systematic Review and Meta-analysis: The Association Between Serum Ustekinumab Trough Concentrations and Treatment Response in Inflammatory Bowel Disease.

Inflammatory Bowel Diseases, 2023
BACKGROUND Optimizing therapy and monitoring response are integral aspects of inflammatory bowel disease treatment. We conducted a systematic review and meta-analysis to determine whether serum ustekinumab trough concentrations during maintenance therapy
A. Vasudevan, V. Tharayil, Laura H. Raffals, D. Bruining, Michelle Becker, M. Murad, E. Loftus   +6 more
semanticscholar   +1 more source

Post-Operative Outcomes in Patients Undergoing Abdominal Surgery for Crohn's Disease Treated with Pre-Operative Ustekinumab: A Systematic Review and Meta-Analysis

World Journal of Colorectal Surgery, 2022
Background: Ustekinumab is a monoclonal antibody targeting interleukins 12 and 23 to treat Crohn's disease. Effects on surgical complications and outcomes are not well understood.
Nancy Gupta, Emanuelle Bellaguarda, Eileen Wafford, Joseph Feuerstein, Vitaliy Y. Poylin   +4 more
doaj   +1 more source

Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis. [PDF]

, 2020
Risankizumab-rzaa (Skyrizi®; AbbVie) is a humanized IgG monoclonal antibody directed against interleukin-23p19 (IL-23p19) indicated for the treatment of moderate-to-severe psoriasis in adults who are candidates for systemic therapy or phototherapy.
Liao, Wilson, Myers, Bridget, Reddy, Vidhatha, Yang, Eric J   +3 more
core   +1 more source

Efficacy, Effectiveness, and Safety of Ustekinumab for the Treatment of Ulcerative Colitis: A Systematic Review

Inflammatory Bowel Diseases, 2023
Objective This study aimed to evaluate ustekinumab efficacy, effectiveness, and safety as a treatment for ulcerative colitis in adult patients. Methods A systematic review of the efficacy, effectiveness, and safety of ustekinumab in ulcerative colitis ...
J. Gisbert, Elizabeth Parody-Rúa, M. Chaparro   +2 more
semanticscholar   +1 more source

Successful Drug Desensitization to Ustekinumab in a Patient with Crohn’s Disease

Case Reports in Gastroenterology, 2021
Ustekinumab is a monoclonal antibody used as treatment for various inflammatory conditions. We present a pediatric patient with Crohn’s disease who did not tolerate infliximab and was then changed to ustekinumab.
Barrie Cohen, Gitit Tomer, Tatyana Gavrilova   +2 more
doaj   +1 more source